Bank of America has adjusted its price target for National Health Investors (NHI, Financial), decreasing it from $91 to $83, while maintaining a Buy rating on the shares. The revision follows recent evaluations of the company's properties, updates from the current quarter, and the timeline for 2025 guidance projections.
Despite the lowered price target, the firm anticipates favorable outcomes for the first quarter, predicting a combination of above and meeting expectations for NHI's results. This positive outlook is part of a broader optimistic view on the earnings season for real estate investment trusts (REITs).
Investors are being advised that the recent assessments point towards a robust performance, underpinning confidence in the company's future prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for National Health Investors Inc (NHI, Financial) is $82.00 with a high estimate of $91.00 and a low estimate of $67.00. The average target implies an upside of 12.62% from the current price of $72.81. More detailed estimate data can be found on the National Health Investors Inc (NHI) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, National Health Investors Inc's (NHI, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for National Health Investors Inc (NHI, Financial) in one year is $71.41, suggesting a downside of 1.92% from the current price of $72.81. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the National Health Investors Inc (NHI) Summary page.
